A dual-action cyclooxygenase (COX)-fatty acid amide hydrolase (FAAH) inhibitor may have therapeutic usefulness as an analgesic, but a key issue is finding the right balance of inhibitory effects. This can be done by the design of compounds exhibiting different FAAH/COX-inhibitory potencies. In the present study, eight ibuprofen analogues were investigated. Ibuprofen (1), 2-(4-Isobutylphenyl)-N-(2-(3-methylpyridin-2-ylamino)-2-oxoethyl)propanamide (9) and N-(3-methylpyridin-2-yl)-2-(4'-isobutylphenyl)propionamide (2) inhibited FAAH with IC(50) values of 134, 3.6 and 0.52 µM respectively. The corresponding values for COX-1 were ~29, ~50 and ~60 µM, respectively. Using arachidonic acid as substrate, the compounds were weak inhibitors of COX-2. However, when anandamide was used as COX-2 substrate, potency increased, with approximate IC(50) values of ~6, ~10 and ~19 µM, respectively. Compound 2 was confirmed to be active in vivo in a murine model of visceral nociception, but the effects of the compound were not blocked by CB receptor antagonists.
A dual-action cyclooxygenase (COX)-n class="Chemical">fatty acidamide hydrolase (FAAH) inhibitor may have therapeutic usefulness as an analgesic, but a key issue is finding the right balance of inhibitory effects. This can be done by the design of compounds exhibiting different FAAH/COX-inhibitory potencies. In the present study, eight ibuprofen analogues were investigated. Ibuprofen (1), 2-(4-Isobutylphenyl)-N-(2-(3-methylpyridin-2-ylamino)-2-oxoethyl)propanamide (9) and N-(3-methylpyridin-2-yl)-2-(4'-isobutylphenyl)propionamide (2) inhibited FAAH with IC(50) values of 134, 3.6 and 0.52 µM respectively. The corresponding values for COX-1 were ~29, ~50 and ~60 µM, respectively. Using arachidonic acid as substrate, the compounds were weak inhibitors of COX-2. However, when anandamide was used as COX-2 substrate, potency increased, with approximate IC(50) values of ~6, ~10 and ~19 µM, respectively. Compound 2 was confirmed to be active in vivo in a murine model of visceral nociception, but the effects of the compound were not blocked by CB receptor antagonists.
Authors: Kelsey C Duggan; Daniel J Hermanson; Joel Musee; Jeffery J Prusakiewicz; Jami L Scheib; Bruce D Carter; Surajit Banerjee; J A Oates; Lawrence J Marnett Journal: Nat Chem Biol Date: 2011-11 Impact factor: 15.040
Authors: Hans Gühring; May Hamza; Marina Sergejeva; Mehmet Ates; Carolin E Kotalla; Catherine Ledent; Kay Brune Journal: Eur J Pharmacol Date: 2002-11-15 Impact factor: 4.432
Authors: Mehmet Ates; May Hamza; Kay Seidel; Carolin E Kotalla; Catherine Ledent; Hans Gühring Journal: Eur J Neurosci Date: 2003-02 Impact factor: 3.386
Authors: Kevin R Kozak; Jeffery J Prusakiewicz; Scott W Rowlinson; Daniel R Prudhomme; Lawrence J Marnett Journal: Biochemistry Date: 2003-08-05 Impact factor: 3.162
Authors: Tyler M Rose; Christopher A Reilly; Cassandra E Deering-Rice; Clinton Brewster; Chelsea Brewster Journal: Bioorg Med Chem Lett Date: 2014-10-28 Impact factor: 2.823
Authors: Liudmila L Mazaleuskaya; Katherine N Theken; Li Gong; Caroline F Thorn; Garret A FitzGerald; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2015-02 Impact factor: 2.089
Authors: Farzin Zobdeh; Ivan I Eremenko; Mikail A Akan; Vadim V Tarasov; Vladimir N Chubarev; Helgi B Schiöth; Jessica Mwinyi Journal: Pharmaceutics Date: 2022-06-01 Impact factor: 6.525
Authors: Angelo D Favia; Damien Habrant; Rita Scarpelli; Marco Migliore; Clara Albani; Sine Mandrup Bertozzi; Mauro Dionisi; Glauco Tarozzo; Daniele Piomelli; Andrea Cavalli; Marco De Vivo Journal: J Med Chem Date: 2012-10-08 Impact factor: 7.446
Authors: Marco Migliore; Damien Habrant; Oscar Sasso; Clara Albani; Sine Mandrup Bertozzi; Andrea Armirotti; Daniele Piomelli; Rita Scarpelli Journal: Eur J Med Chem Date: 2015-12-23 Impact factor: 6.514